Concepedia

EPIC: Phase III Trial of Cetuximab Plus Irinotecan After Fluoropyrimidine and Oxaliplatin Failure in Patients With Metastatic Colorectal Cancer

Alberto Sobrero, Joan Maurel, Louis Fehrenbacher, Werner Scheithauer, Yousif Abubakr, Manfred P. Lutz, M. E. Vega-Villegas, Cathy Eng, E.U. Steinhauer, Jana Prausová,

Journal of Clinical Oncology · 2008 · 945 citations · 30 references

DOIFull text

Open access

Abstract

Cetuximab and irinotecan improved PFS and RR, and resulted in better QOL versus irinotecan alone. OS was similar between study groups, possibly influenced by the large number of patients in the irinotecan arm who received cetuximab and irinotecan poststudy.

References

30

The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology

N.K. Aaronson, Sam H. Ahmedzai, Bengt Bergman et al. · JNCI Journal of the National Cancer Institute · 1993 · 15.4K citations

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak et al. · New England Journal of Medicine · 2001 · 11.4K citations · Full text

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

Herbert I. Hurwitz, Louis Fehrenbacher, William Novotny et al. · New England Journal of Medicine · 2004 · 10.9K citations · Full text

Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer

David Cunningham, Yves Humblet, Salvatore Siena et al. · New England Journal of Medicine · 2004 · 5K citations · Full text

Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer

Aimery de Gramont, Arié Figer, Michel Seymour et al. · Journal of Clinical Oncology · 2000 · 3.8K citations